Martinot-Peignoux, Michele

Publishing since 1989 (Dinosaur)

Has published 63 publications in 22 years

Number of publications published per year by Martinot-Peignoux, Michele. (Source : PubMed)

Distribution of publications types for Martinot-Peignoux, Michele. (Source : PubMed)
(a publication can be of different types, so total may exceed publications count)

Recent publications

•  Cardoso AC, Moucari R, Figueiredo-Mendes C, Ripault MP, Giuily N, Castelnau C, Boyer N, Asselah T, Martinot-Peignoux M, Maylin S, Carvalho-Filho RJ, Valla D, Bedossa P, Marcellin P. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: Incidence and survival in hepatitis C patients with advanced fibrosis.  J. Hepatol.  2010  
•  Halfon P, Martinot-Peignoux M, Khiri H, Marcellin P. Quantification of genotype 4 serum samples: Impact of hepatitis C virus genetic variability.  Hepatology  2010  
•  Moucari R, Ripault MP, Martinot-Peignoux M, Voitot H, Cardoso AC, Stern C, Boyer N, Maylin S, Nicolas-Chanoine MH, Vidaud M, Valla D, Bedossa P, Marcellin P. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4.  Gut  2009;58;12  
•  Martinot-Peignoux M, Stern C, Maylin S, Ripault MP, Boyer N, Leclere L, Castelnau C, Giuily N, El Ray A, Cardoso AC, Moucari R, Asselah T, Marcellin P. Twelve weeks posttreatment follow-up is as relevant as 24 weeks to determine the sustained virologic response in patients with hepatitis C virus receiving pegylated interferon and ribavirin.  Hepatology  2009  
•  Martinot-Peignoux M, Khiri H, Leclere L, Maylin S, Marcellin P, Halfon P. Clinical performances of two real-time PCR assays and bDNA/TMA to early monitor treatment outcome in patients with chronic hepatitis C.  J. Clin. Virol.  2009;46;3  
•  Halfon P, Martinot-Peignoux M, Cacoub P. The myth of occult hepatitis C infection.  Hepatology  2009;50;5  
•  Moucari R, Korevaar A, Lada O, Martinot-Peignoux M, Boyer N, Mackiewicz V, Dauvergne A, Cardoso AC, Asselah T, Nicolas-Chanoine MH, Vidaud M, Valla D, Bedossa P, Marcellin P. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study.  J. Hepatol.  2009;50;6  
•  Moucari R, Mackiewicz V, Lada O, Ripault MP, Castelnau C, Martinot-Peignoux M, Dauvergne A, Asselah T, Boyer N, Bedossa P, Valla D, Vidaud M, Nicolas-Chanoine MH, Marcellin P. Early serum HBsAg drop: a strong predictor of sustained virological response to pegylated interferon alfa-2a in HBeAg-negative patients.  Hepatology  2009;49;4  
•  Maylin S, Martinot-Peignoux M, Ripault MP, Moucari R, Cardoso AC, Boyer N, Giuily N, Castelnau C, Pouteau M, Asselah T, Nicolas-Chanoine MH, Marcellin P. Sustained virological response is associated with clearance of hepatitis C virus RNA and a decrease in hepatitis C virus antibody.  Liver Int.  2009;29;4  
•  Moucari R, Martinot-Peignoux M, Mackiewicz V, Boyer N, Ripault MP, Castelnau C, Leclere L, Dauvergne A, Valla D, Vidaud M, Nicolas-Chanoine MH, Marcellin P. Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-alpha2a.  Antivir. Ther. (Lond.)  2009;14;8  

[ See timeline ] [ See all publications ]